Research and Development Costs. Development Costs incurred in the conduct of the Additional Research Programs and Joint Development Programs will be borne in accordance with Exhibit D. Development Costs incurred in the conduct of the Independent Additional Study Development Plan(s) (as applicable) will be borne in accordance with Exhibit D.
Research and Development Costs. All research and Development costs will be the responsibility of Flexion.
Research and Development Costs. Denali shall be responsible for FTE costs incurred by Licensor and F-star Ltd in relation to each Fcab Discovery Plan and mAb2 Development Plan as set forth in the applicable Fcab Discovery Plan or mAb2 Development Plan, and subject to the following. For the TfR Fcab Discovery Plan Denali will fund [***] FTEs per Calendar Quarter. Payment of such sums shall be paid in advance in accordance with the budget/FTE allocation agreed as a part of each Fcab Discovery Plan and mAb2 Development Plan. Promptly following the end of each Calendar Quarter, Licensor shall provide to Denali a report with the actual costs incurred during such Calendar Quarter, and the Parties shall review those actual costs against the budget/FTE allocation. Following such review, and upon mutual written agreement between the Parties, the budget/FTE allocation may be increased or decreased. On an Accepted Fcab Target-by-Accepted Fcab Target basis, Denali’s obligation to fund such FTE costs incurred in relation to a Fcab Discovery Plan shall terminate on the earlier of (a) [***], and (b) [***]; provided that upon mutual written agreement following discussion at the JSC, Denali may extend such commitment to fund costs for a particular Fcab Discovery Plan.
Research and Development Costs. Except where AstraZeneca is carrying out additional research and development activities to bring forward Nominated Compounds all other research and Development costs will be the responsibility of Flexion, including any activities which Flexion undertakes pre-acceptance in order to determine whether a Nominated Compound meets the Acceptance Criteria.
Research and Development Costs. Subject to this Paragraph 1 and Paragraph 2 of this Exhibit D-1, upon exercise of the [***] Profit Share Option, the Parties shall share all Research and Development Costs incurred on or after the exercise of the [***] Profit Share Option in connection with the Development of the [***] Product(s), including preclinical, CMC, clinical development, and companion diagnostic development but excluding, for clarity, any Research and Development Costs incurred with respect to a Competing Study or Proprietary Compound Combination Study, as follows:
Research and Development Costs. Software research and development costs are accounted for in accordance with SFAS No. 86, Accounting for the Costs of Computer Software to Be Sold, Leased or Otherwise Marketed. The Company will capitalize material software-development costs incurred after the technological feasibility of software-development projects has been established. The Company determines technological feasibility has been established at the time when a working model of the software has been completed. Historically, the time incurred between when a working model of the software has been completed and general release to customers has been short, and therefore, the costs have been insignificant. As a result, for the year ended December 31, 2006, the period from January 1, 2007 to April 11, 2007, and the period from January 29, 2007 to December 21, 2007, no software development costs met the criteria for capitalization. Cambium Learning, Inc. (Predecessor) and VSS-Cambium Holdings, LLC (Successor) Notes to Consolidated Financial Statements (continued)
Research and Development Costs. If ***, where any development work is to be conducted pursuant to Clause 4 hereto, the costs of such development work as agreed pursuant to any agreed Development Plan shall be shared as follows:
Research and Development Costs. Except as otherwise provided in Section 5.2, GBI shall fund the development of the Products at its sole cost and expense as more particularly set forth in the Development Plan attached as Exhibit A. Upon commercialization of the Products, GBI shall provide, at its own cost and expense, on-going research and development and training support of the Products, as more specifically provided in Sections 12.2 and 12.3 of this Agreement.
Research and Development Costs. The first 2 million Euros of costs of R&D Projects in each calendar year during the term of this Agreement shall be borne by Arcelor Commercial. Any costs of R&D Projects in excess of 2 million Euros in any such calendar year shall be paid or reimbursed by Noble BV. Arcelor Commercial shall endeavor to keep Noble BV reasonably informed, through the Parties' coordination meetings pursuant to Section 7, of the R&D Projects costs incurred and shall notify Noble BV when Arcelor Commercial becomes aware that such costs are closely approaching the 2 million Euros threshold. The costs shall be determined in accordance with (a) Arcelor Commercial’s reasonable cost calculation methods for direct research and development expense, including direct labor salaries and benefits, technical writers, data entry, internal and external testing, research materials and supplies and other direct expenses, and (b) reasonable allocations of indirect research and development expense, including labor salaries and benefits of department managers, system managers and other employees engaged in R&D Projects, equipment rental, materials and supplies, and other costs reasonably related to R&D Projects.
Research and Development Costs. Research and development costs expected to yield a return over a period in excess of the current financial year are car- ried as assets at the cost of manufacture. Where this is not the case, the costs are charged to the financial year in which they are incurred. The capitalised costs are written down by the straight-line method depending on the economic and commercial prospects (3 to 5 years). In the year of investment, the costs of research and development were written off star- ting from the month following the date when they were ope- rational. Licences, Patents, Concessions, Know-how Investments in licences, patents, trademarks etc. are capitali- sed and subject to straight-line depreciation over a period of five years. Concessions are written down by the straight-line method for the life of the agreement. The manufacturing cost of intangibles other than those acquired from third parties is determined by the direct costing method. In the year of investment, the licenses, patents, concessions and know-how were written-off from the month following the date when they were operational. P 40 Financial Information - Annual Report 200 1 I CARESTEL GROUP I www .car xxxxx.xxx
